6533b856fe1ef96bd12b1e13

RESEARCH PRODUCT

Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death

Angela VitranoNipon ChattipakornGiuseppina CalvarusoLiana CucciaLuigi MancusoCalogera GerardiJohn WalkerPaolo RiganoMichel AngastiniotisLuciano ProssomaritiVincenzo CarusoAldo FilosaSaveria CampisiArintaya PhrommintikulLorella PitroloPaul TelferPaolo CianciulliHala S. HamzaAurelio MaggioAndroulla ElefteriouMarcello CapraBarone Rita

subject

AdultMaleCardiac function curvemedicine.medical_specialtyHeart diseaseThalassemiaThalassemia major Left ventricular ejection fraction (LVEF) Chelation Echocardiography Cardiac magnetic resonance T2*Young AdultInternal medicinemedicineHumansMolecular BiologySurvival analysisModels StatisticalEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeCell BiologyHematologyStroke volumemedicine.diseaseClinical trialDeath Sudden CardiacROC CurveEchocardiographyHeart failurecardiovascular systemCardiologyMolecular MedicineFemalebusiness

description

Cardiac damage remains a major cause of mortality among patients with thalassemia major. The detection of a lower cardiac magnetic resonance T2* (CMR-T2*) signal has been suggested as a powerful predictor of the subsequent development of heart failure. However, the lack of worldwide availability of CMR-T2* facilities prevents its widespread use for follow-up evaluations of cardiac function in thalassemia major patients, warranting the need to assess the utility of other possible procedures. In this setting, the determination of left ventricular ejection fraction (LVEF) offers an accurate and reproducible method for heart function evaluation. These findings suggest a reduction in LVEF≥7%, over time, determined by 2-D echocardiography, may be considered a strong predictive tool for the detection of thalassemia major patients with increased risk of cardiac death. The reduction of LVEF≥7% had higher (84.76%) predictive value. Finally, Kaplan-Meier survival curves of thalassemia major patients with LVEF≥7% showed a statistically significant decreased probability of survival for heart disease (p=0.0022). However, because of limitations related to the study design, such findings should be confirmed in a large long-term prospective clinical trial.

https://doi.org/10.1016/j.bcmd.2012.12.002